Nektar Therapeutics
- Address
- 455 Mission Bay Boulevard South
Sponsor Overview
Specializations
Autoimmune Hair Loss
Nektar Therapeutics is involved in clinical research for alopecia areata, with a focus on severe to very severe disease and the restoration of scalp hair growth.
- Severe alopecia areata
- Hair loss reduction
- Immune-mediated follicle disease
This area reflects interest in therapies aimed at modifying the underlying immune dysregulation associated with patchy and extensive hair loss.
Inflammatory Skin Disease
The sponsor also supports research in atopic dermatitis, including adult patients with moderate-to-severe disease and persistent inflammatory skin symptoms.
- Moderate-to-severe atopic dermatitis
- Skin inflammation
- Eczema symptom control
Clinical activity in this field centers on improving disease burden in biologic-naive patients with active eczema.
Immune-Mediated Therapeutics
Across both programs, Nektar Therapeutics is engaged in research targeting immune-mediated disorders with relevance to dermatologic autoimmunity and chronic inflammation.
- Immune pathway modulation
- Dermatology-focused immunotherapy
- Chronic inflammatory conditions
The therapeutic emphasis spans conditions where altered immune signaling contributes to persistent skin and hair follicle disease.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Efficacy and Safety Evaluation of Rezpegaldesleukin in Biologic-Naive Adults with Moderate-to-Severe Atopic Dermatitis: A Phase 2b Randomized, Double-Blind, Placebo-Controlled Trial | public Bulgariapublic Croatiapublic Czechiapublic Germanypublic Hungarypublic Polandpublic Spain | Not Recruiting |
| Efficacy and Safety Evaluation of Rezpegaldesleukin in Severe to Very Severe Alopecia Areata: A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study | public Poland | Not Recruiting |
| Phase 3 Randomized Double‑Blind Placebo‑Controlled Study of Rezpegaldesleukin (NKTR‑358) Monotherapy in Patients ≥12 Years with Moderate‑to‑Severe Atopic Dermatitis | public Belgiumpublic Bulgariapublic Czechiapublic Greecepublic Lithuaniapublic Spain | Not Yet Recruiting |
| Phase 3 Randomized, Double‑Blind, Placebo‑Controlled Study of Subcutaneous Rezpegaldesleukin (NKTR‑358) in Patients ≥12 Years with Moderate‑to‑Severe Atopic Dermatitis | public Czechiapublic Latviapublic Portugal | Not Yet Recruiting |
Data & Insights
This sponsor works with 1 molecule, of which 1 is not being studied by other sponsors.
This sponsor has worked with 102 sites across their trial portfolio.
Therapeutic Focus
- 1.Immune System Diseases4 trials339 other sponsors
- 2.Skin and Connective Tissue Diseases4 trials257 other sponsors
Partnered Research Centres
102 centres- Address
- Seliu G. 64, Vilniaus M. Sav., 08109 Vilnius
- Address
- Ul. Polskiego Czerwonego Krzyza 26, 33-100 Tarnow
- Address
- Dragoumi Ionos 5 I, 161 21 Athens
- Address
- Ploshtad Svoboda 1, 2600 Dupnitsa
- Address
- 28. Rijna 3348/65, Moravska Ostrava, 702 00 Ostrava
- Address
- Jonavos G. 7, Kauno M. Sav., 44192 Kaunas
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Nektar Therapeutics.
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.